GAINESVILLE, Fla. -- Hispanic women with hypertension and coronary artery disease respond better to drug regimens aimed at controlling high blood pressure than non-Hispanic white women, University of Florida researchers report.
A UF study described in the current issue of the Journal of Womens Health revealed that when treated with either of two commonly prescribed medication strategies, Hispanic women achieved greater blood pressure control and were half as likely as white women to suffer adverse outcomes such as heart attack, stroke or death from any cause. The findings provide new data on a population of ethnic women who have been all but absent from such research.
The study is unique in that we enrolled a substantial number of women and a substantial number of Hispanic patients from a variety of different Hispanic regions. As a result, we have data that enabled us to really fully evaluate the treatment of hypertension in this ethnically diverse group, said Rhonda Cooper-DeHoff, Pharm.D, M.S., a research assistant professor of medicine and associate director of the clinical research program in cardiovascular medicine at UFs College of Medicine.
UF researchers studied 22,500 patients enrolled in the landmark International Verapamil SR-Trandolapril study, known as INVEST, and tracked a subgroup of 5,017 Hispanic and 4,710 non-Hispanic white women who were randomly assigned to a drug strategy containing either a sustained release form of the calcium antagonist verapamil or the beta-blocker atenolol.
The INVEST study enrolled more Hispanic patients than any other hypertension trial to date, Cooper-DeHoff said, and included Hispanic participants from the mainland United States, Puerto Rico, Cuba, Mexico, Canada, Guatemala, Panama and El Salvador.
After 24 months of follow-up, researchers found that both treatment strategies worked and worked better in the Hispanic women.